Huang W, Molitch ME. Evaluation and management of galactorrhea. Am Fam Physician. 2012;85(11):1073-1080.
Jameson JL, DeGroot LJ, et al., eds. Endocrinology: Adult and Pediatric. 7th ed. Elsevier Saunders; 2016.
Patrascu OM, Chopra D, Dwivedi S. Galactorrhoea: report of two cases. Maedica (Bucur). 2015;10(2):136-139.
Lee SJ, Trikha S, Moy L, et al.; Expert Panel on Breast Imaging. ACR Appropriateness Criteria® evaluation of nipple discharge. J Am Coll Radiol. 2017;14(5S):S138-S153.
Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013;6(3):168-175.
Vroonen L, Daly AF, Beckers A. Epidemiology and management challenges in prolactinomas. Neuroendocrinology. 2019;109(1):20-27.
Weaver M, Stuckey A. Benign breast disorders. Obstet Gynecol Clin North Am. 2022;49(1):57-72.
Patel BK, Falcon S, Drukteinis J. Management of nipple discharge and the associated imaging findings. Am J Med. 2015;128(4):353-360.
Wildemberg LE, Fialho C, Gadelha MR. Prolactinomas. Presse Med. 2021;50(4):104080.
Levine S, Muneyyirci-Delale O. Stress-induced hyperprolactinemia: pathophysiology and clinical approach. Obstet Gynecol Int. 2018;2018:9253083.
Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101290.
Atluri S, Sarathi V, Goel A, et al. Etiological profile of galactorrhoea. Indian J Endocrinol Metab. 2018;22(4):489-493.
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.
Vilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of hyperprolactinemia. Arq Bras Endocrinol Metabol. 2014;58(1):9-22.
Faje A, Tritos NA, Swearingen B, et al. Neuroendocrine disorders: pituitary imaging. Handb Clin Neurol. 2016;136:873-885.
Samperi I, Lithgow K, Karavitaki N. Hyperprolactinaemia. J Clin Med. 2019;8(12):2203.
Vilar L, Abucham J, Albuquerque JL, et al. Controversial issues in the management of hyperprolactinemia and prolactinomas – an overview by the neuroendocrinology department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2018;62(2):236-263.
Kukreti P, Ali W, Jiloha RC. Rising trend of use of antidepressants induced non-puerperal lactation: a case report. J Clin Diagn Res. 2016;10(6):VD01-VD02.
Egberts AC, Meyboom RH, De Koning FH, et al. Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol. 1997;44(3):277-281.
Özten E, Hizli Sayar G, Göğçegöz Gül I, et al. Sertraline induced galactorrhea. Noro Psikiyatr Ars. 2015;52(2):202-203.
Lopes MBS. Pathology of prolactinomas: any predictive value?. Pituitary. 2020;23(1):3-8.
Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008;37(1):67-99.
Glocker C, Grohmann R, Engel R, et al. Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015. Eur Arch Psychiatry Clin Neurosci. 2021;271(8):1425-1435.
Javanbakht A, Zanazzi G. Educational case: pituitary adenoma. Acad Pathol. 2021;8 : 23742895211037028.
Abouaf L, Vighetto A, Lebas M. Neuro-ophthalmologic exploration in non-functioning pituitary adenoma. Ann Endocrinol (Paris). 2015;76(3):210-219.
Prolactin. Quest Diagnostics. Accessed March 9, 2022. https://testdirectory.questdiagnostics.com/test/test-detail/746/prolactin?cc=MASTER&msclkid=1070bfb6b87711ecb301322707d0a9eb
Hamoud Ali A. Pituitary microadenoma. Radiopaedia. Updated July 25, 2022. Accessed September 27, 2022. https://radiopaedia.org/articles/pituitary-microadenoma
Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27(5):485-534.
Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001;86(11):5256-5261.
Cabergoline. Dynamed. Accessed April 15, 2022. https://www.dynamed.com/drug-monograph/cabergoline
Bromocriptine. Dynamed. Accessed April 15, 2022. https://www.dynamed.com/drug-monograph/bromocriptine
Klibanski A. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued?. J Clin Endocrinol Metab. 2009;94(7):2247-2249.
Biswas M, Smith J, Jadon D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf). 2005;63(1):26-31.
Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(1):43-51.
Losa M, Mortini P, Barzaghi R, et al. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab. 2002;87(7):3180-3186.
Prete A, Corsello SM, Salvatori R. Current best practice in the management of patients after pituitary surgery. Ther Adv Endocrinol Metab. 2017;8(3):33-48.
Raymond JP, Goldstein E, Konopka P, et al. Follow-up of children born of bromocriptine-treated mothers. Horm Res. 1985;22(3):239-246.
Huang W, Molitch ME. Pituitary tumors in pregnancy. Endocrinol Metab Clin North Am. 2019;48(3):569-581.
Gonzalez JG, Elizondo G, Saldivar D, et al. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med. 1988;85(2):217-220.
De Berardis D, Fornaro M, Serroni N, et al. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Recent Pat Endocr Metab Immune Drug Discov. 2014;8(1):30-37.
Leung AKC, Pacaud D. Diagnosis and management of galactorrhea. Am Fam Physician. 2004;70(3):543-550.
Peña KS, Rosenfeld JA. Evaluation and treatment of galactorrhea. Am Fam Physician. 2001;63(9):1763-1770.